Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802116 | 1.00 | ADRB3 (0.47) | ADRB3ADRB1ADRB2POLBLMNA | |
| SCHEMBL2294588 | 0.90 | ADRB3 (0.49) | ADRB3ADRB1ADRB2MAPT | |
| SCHEMBL12380677 | 0.90 | ADRB3 (0.49) | ADRB3ADRB1ADRB2MAPT | |
| SCHEMBL5264326 | 0.90 | ADRB3 (0.49) | ADRB3ADRB1ADRB2MAPT | |
| SCHEMBL5261882 | 0.90 | ADRB3 (0.49) | ADRB3ADRB1ADRB2MAPT | |
| SCHEMBL4804960 | 0.90 | ADRB3 (0.50) | ADRB3ADRB1ADRB2LMNAMEN1 | |
| SCHEMBL4804931 | 0.90 | ADRB3 (0.50) | ADRB3ADRB1ADRB2LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL2294584 | 0.90 | ADRB3 (0.48) | ADRB3ADRB1ADRB2LMNAMEN1 | |
| SCHEMBL4805686 | 0.87 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4805693 | 0.87 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7453010-B2 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100283-A1 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | CHRM1, CHRM2, C1R | ADRB3 22/4885ADRB1 29/4885ADRB2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.